As of Thursday close, Guardant Health Inc.’s (NASDAQ:GH) stock was down -$0.6, moving down -1.66 percent to $35.54. The average number of shares traded per day over the past five days has been 1,621,980 shares. 2 times new highs have been achieved over the past 5 days, with a -$1.87 fall in that time frame. In the last twenty days, the average volume was 1,386,825, while in the previous 50 days, it was 2,226,600.
Since last month, GH stock retreated -2.23%. Shares of the company fell to $34.75 on 07/06/23, the lowest level in the past month. A 52-week high of $62.75 was reached on 07/27/23 after having rallying from a 52-week low of $20.67. Since the beginning of this year, GH’s stock price has risen by 30.66% or $8.34, and marked a new high 20 times. However, the stock has declined by -43.36% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
GH stock investors should be aware that Guardant Health Inc. (GH) stock had its last reported insider trading activity 50 days ago on Jun 15. Joyce Meghan V., the Director of the company, disposed of 2,766 shares for $37.55 on Jun 15. It resulted in a $103,863 divestment by the insider. Kalia Kumud added 2,981 shares at an average price of $32.71 on Jun 09. The insider now owns 5,193 shares following the transaction. On Mar 15, Co-Chief Executive Officer Eltoukhy Helmy bought 8,600 shares at $26.15 apiece. The transaction was valued at $224,928.
Financial Health
In the three months ended March 30, Guardant Health Inc.’s quick ratio stood at 5.20, while its current ratio was 5.40, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 63.20% percent. Based on annual data, GH earned $293.21 million in gross profit and brought in $449.54 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -46.00%. Return on equity (ROE) for the past 12 months was -530.40%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. GH’s revenue rose 25.34% to $126.89 million during the quarter, while net income inched up to $128.71 million. While analysts expected Guardant Health Inc. to report -$1.31 quarterly earnings, the actual figure was -$1.3 per share, beating the consensus estimate by 0.80%. During the quarter, the company generated -$124.08 million in EBITDA. The liabilities of Guardant Health Inc. were 1.56 billion at the end of its most recent quarter ended March 30, and its total debt was $1.37 billion. The value of shareholders’ equity is $102.77 million.
Technical Picture
This quick technical analysis looks at Guardant Health Inc.’s (GH) price momentum. With a historical volatility rate of 47.79%, the RSI 9-day stood at 35.91% on 03 August.
With respect to its five-day moving average, the current Guardant Health Inc. price is down by -5.00% percent or -$1.87. At present, GH shares trade -2.26% below its 20-day simple moving average and +42.10% percent above its 100-day simple moving average. However, the stock is currently trading approximately +15.39% above its SMA50 and -27.11% below its SMA200.
Stochastic coefficient K was 20.92% and Stochastic coefficient D was 45.41%, while ATR was 1.44. Given the Stochastic reading of 12.73% for the 14-day period, the RSI (14) reading has been calculated as 43.05%. As of today, the MACD Oscillator reading stands at -1.13, while the 14-day reading stands at -1.15.
Analyst Ratings
Guardant Health Inc. (GH) has been rated Buy by analysts. According to 0 brokerage firms, GH is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Guardant Health Inc. stock as buy, with 17 recommending it as overweight.
With a median target price of $53.00, the current consensus forecast for the stock is $30.00 – $85.00. Based on these forecasts, analysts predict Guardant Health Inc. (GH) will achieve an average price target of $54.18.
